Healthcare > Pharmaceuticals & Biotechnology
•2430 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2430)
| Company | Market Cap | Price |
|---|---|---|
|
BHVN
Biohaven Ltd.
BHVN's Kv7 ion channel modulation platform (BHV-7000) and TRPM3 antagonist (BHV-2100) position the company in Ion Channel Modulators, a key neuroscience/pain modality.
|
$1.16B |
$10.97
+9.59%
|
|
OLMA
Olema Pharmaceuticals, Inc.
Olema is a biotechnology company focused on oncology therapies, including palazestrant in ER+ breast cancer.
|
$1.15B |
$16.80
+1.91%
|
|
AZTA
Azenta, Inc.
Genewiz genomic sequencing and broader SMS/Multiomics services align with Contract Research Organizations.
|
$1.15B |
$25.04
+2.96%
|
|
GHRS
GH Research PLC
GH Research's focus on neuropsychiatric drug development (CNS/psychiatric disorders) via 5-MeO-DMT therapies.
|
$1.14B |
$18.32
+3.27%
|
|
SPRY
ARS Pharmaceuticals, Inc.
Neffy uses a proprietary Drug Delivery Platform enabling intranasal delivery of epinephrine.
|
$1.10B |
$11.36
+1.88%
|
|
QURE
uniQure N.V.
Core business is development and commercialization of gene therapies (e.g., AMT-130) using viral vectors, i.e., direct gene therapy products.
|
$1.10B |
$17.59
+4.64%
|
|
COLL
Collegium Pharmaceutical, Inc.
Jornay PM, Belbuca, Xtampza ER, and Nucynta are all oral small-molecule therapeutics, representing major product categories in Collegium's portfolio.
|
$1.09B |
$34.42
+4.18%
|
|
NEO
NeoGenomics, Inc.
MRD-related diagnostics and companion diagnostics align with therapy selection and monitoring.
|
$1.08B |
$8.37
+2.57%
|
|
GERN
Geron Corporation
Geron directly develops and commercializes RYTELO (imetelstat), an oncology therapeutic indicated for lower-risk MDS.
|
$1.07B |
$1.69
|
|
CMPX
Compass Therapeutics, Inc.
Compass Therapeutics is an oncology-focused biotech developing cancer therapies, anchoring its business in oncology.
|
$1.07B |
$5.99
-8.27%
|
|
PCRX
Pacira BioSciences, Inc.
Pacira's pMVL-based Drug Delivery Platforms enable extended-release formulations used in EXPAREL and ZILRETTA.
|
$1.06B |
$24.75
+3.73%
|
|
XERS
Xeris Biopharma Holdings, Inc.
Xeris's XeriSol and XeriJect drug-delivery platforms enable stable, ready-to-use injectable formulations, a core differentiator.
|
$1.06B |
$6.38
+4.17%
|
|
URGN
UroGen Pharma Ltd.
ZUSDURI (UGN-102) is an oncology therapeutic developed by UroGen, placing the company in Biotech - Oncology.
|
$1.06B |
$22.58
+5.56%
|
|
AMPH
Amphastar Pharmaceuticals, Inc.
Amphastar is advancing biosimilar programs (AMP-004) and positions biosimilars as a core growth pillar.
|
$1.05B |
$22.84
+4.72%
|
|
CVAC
CureVac N.V.
CureVac's core focus is oncology immunotherapies and cancer vaccines built on its mRNA platform (Biotech - Oncology).
|
$1.05B |
$4.66
|
|
ORIC
ORIC Pharmaceuticals, Inc.
ORIC develops oncology therapies (e.g., ORIC-944, ORIC-114, ORIC-533) targeting cancer resistance, placing it in Biotech - Oncology.
|
$1.05B |
$10.75
+5.08%
|
|
KALV
KalVista Pharmaceuticals, Inc.
EKTERLY (sebetralstat) is KalVista's lead asset and is an oral small-molecule therapeutic for acute hereditary angioedema, directly reflecting their product category.
|
$1.04B |
$20.50
+4.78%
|
|
SVRA
Savara Inc.
Molgramostim is a recombinant GM-CSF protein delivered as an inhalation therapy; directly a recombinant protein/enzymes product.
|
$1.00B |
$5.58
-3.79%
|
|
VTYX
Ventyx Biosciences, Inc.
VTX assets are oral small molecule therapeutics for autoimmune/inflammatory diseases (NLRP3 inhibitors).
|
$998.32M |
$14.00
|
|
VERV
Verve Therapeutics, Inc.
Verve Therapeutics' core offering is in vivo gene therapy using base editing delivered to liver cells, aligning with Biotech - Gene Therapy.
|
$988.30M |
$11.13
|
|
RAPT
RAPT Therapeutics, Inc.
RAPT's pipeline includes oncology-focused assets under Biotech - Oncology (tivumecirnon) and broader oncology immunotherapy focus.
|
$959.52M |
$57.99
-0.04%
|
|
FTRE
Fortrea Holdings Inc.
Fortrea operates as a standalone contract research organization providing outsourced clinical development services.
|
$959.11M |
$10.38
+2.82%
|
|
OMER
Omeros Corporation
Narsoplimab and zaltenibart OMS906 are monoclonal antibody therapeutics, a core product class for Omeros.
|
$958.91M |
$13.94
-1.10%
|
|
OPK
OPKO Health, Inc.
ModeX Therapeutics' multi-specific antibodies represent a bispecific antibody product category.
|
$951.95M |
$1.23
+1.65%
|
|
JANX
Janux Therapeutics, Inc.
Company focuses on tumor-activated oncology therapies (TRACTr/TRACIr), placing JANX squarely in Biotech - Oncology.
|
$951.54M |
$15.81
+4.08%
|
|
PHAT
Phathom Pharmaceuticals, Inc.
VOQUEZNA (vonoprazan) is an oral small-molecule therapeutic (P-CAB) with GERD and H. pylori indications, representing the company’s core product line.
|
$938.32M |
$13.19
+4.56%
|
|
SANA
Sana Biotechnology, Inc.
Sana's lead platform is HIP-modified cell therapy (ex vivo) for allogeneic cell transplantation.
|
$937.61M |
$3.52
+1.30%
|
|
XNCR
Xencor, Inc.
Company develops and advances bispecific antibodies (XmAb 2+1 formats) for oncology and autoimmune indications.
|
$932.62M |
$13.05
+4.82%
|
|
ATAI
Atai Beckley N.V
Acquisition of IntelGenx adds drug delivery platforms (oral thin-film) powering VLS-01 and related assets.
|
$919.51M |
$4.16
-3.03%
|
|
SDGR
Schrödinger, Inc.
The company operates a proprietary drug discovery pipeline with programs in oncology, aligning with Biotech - Oncology.
|
$909.02M |
$12.36
+2.49%
|
|
ABUS
Arbutus Biopharma Corporation
AB-101 is described as an oral small-molecule PD-L1 inhibitor, representing an oral small molecule therapeutics product line.
|
$907.77M |
$4.71
+0.75%
|
Showing page 9 of 25 (2430 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
